A Phase 1 interventional study of AP31969 and Placebo in Healthy Volunteers, sponsored by Acesion Pharma. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Acesion Pharma · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Arrhythmias, Cardiac with a site in Netherlands — 13 open to participants now, 18 under way, none of them phase 3. Arrhythmias, Cardiac · Netherlands.
Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, this one is the 25th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is the only one in phase 1, and was the 65th registered.
1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →13 of the 72 studies in Arrhythmias, Cardiac with a site in Netherlands are open now. Recruiting first, the newest first:
Biotronik, Inc. · Sites in Netherlands, United States, Australia and 5 more countries
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Netherlands, United States, Canada and 3 more countries
Ages 18–99
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 4 more countries
Ages 18+
Stereotaxis · Sites in Netherlands, Denmark, Lithuania and 1 more country
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 167 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 8
First in 1983; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 92 is close to the median of 100 across 517 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 240 across the 33 interventional studies, 544 across the 38 observational. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 72 have an industry lead sponsor. The 10 most frequent:
Acesion Pharma is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Acesion Pharma has 1 study filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
7 of the studies in Arrhythmias, Cardiac with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05890716Idoven 1903 S.L.AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM) | 2026-12 |
| NCT04735016Medtronic Cardiac Ablation SolutionsDiamondTemp Global Registry | 2026-12-31 |
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
| NCT06658899Cardurion Pharmaceuticals, Inc.A Phase 2 Study of CRD-4730 in CPVT | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the safety and tolerability of single doses (Part A) and multiple doses (Part B) of AP31969 in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive a single oral dose of AP31969 or matching placebo in 1 of 5 groups. Participants in an additional food effect assessment group will be randomized to receive 2 single oral doses of AP31969 or matching placebo; 1 dose in fasted and 1 dose in fed state in a 2-period, fixed-sequence design (first fasted, then fed with at least 1 week washout between periods).
Drug: AP31969 · Drug: Placebo
Participants will be randomized to receive multiple oral doses of AP31969 or matching placebo for 10 days in 1 of 4 groups.
Drug: AP31969 · Drug: Placebo
Oral tablets
Oral tablets
Number of Participants who Experienced an Adverse Event
Time frame: Up to a maximum of 48 days
Parts A and B: Maximum Observed Plasma Concentration (Cmax) of AP31969
Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12
Parts A and B: Time to Cmax (tmax) of AP31969
Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12
Parts A and B: Terminal Elimination Half-life of AP31969
Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 12
Part A: Area Under the Plasma Concentration Time Curve (AUC) from Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of AP31969
Time frame: Part A: Day 1 to Day 4
Part A: AUC from Time 0 Extrapolated to Infinity (AUC0-inf) of AP31969
Time frame: Part A: Day 1 to Day 4
Part B: AUC Over a Dosing Interval Tau (AUCtau) of AP31969
Time frame: Part B: Day 1 to Day 10
Part A: Apparent Clearance of AP31969
Time frame: Part A: Day 1 to Day 4
Part B: Apparent Clearance at Steady State of AP31969
Time frame: Part B: Day 1 to Day 10
Parts A and B: Apparent Volume of Distribution at Terminal Phase of AP31969
Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 10
Part B: Accumulation Ratio of AP31969
Time frame: Part B: Day 1 to Day 10
Parts A and B: Dose Normalized Cmax of AP31969
Time frame: Part A: Day 1 to Day 4; Part B: Day 1 to Day 10
Part A: Dose Normalized AUC0-last of AP31969
Time frame: Part A: Day 1 to Day 4
Part A: Dose Normalized AUC0-inf of AP31969
Time frame: Part A: Day 1 to Day 4
Part B: Dose Normalized AUCtau of AP31969
Time frame: Part B: Day 1 to Day 10
Part A: Food Effect on Cmax of AP31969
Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group
Part A: Food Effect on AUC0-last of AP31969
Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group
Part A: Food Effect on AUC0-inf of AP31969
Time frame: Part A: Day 1 to Day 4 of fed and fasted treatment periods of the food effect assessment group
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Mar 2025, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AP31969
Acesion Pharma